Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer

NCT05954871 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Non-Small Cell Lung Cancer

Interventions

DRUG: GDC-1971
DRUG: Osimertinib
DRUG: Cetuximab

Sponsor

Genentech, Inc.